Macropa-Based 225Ac-Labeled RGD Peptides for Targeted Alpha Therapy
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.6c00344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Hiroaki Echigo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa920-1192, Japan. Hauptthemen laut MEDLINE: Oligopeptides, Actinium, Glioblastoma, Alpha Particles. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Terumo Foundation for Life Sciences and Arts.
Abstract (Originalsprache)
Macropa has formed more stable complexes with 225Ac, although DOTA has been extensively used as a chelator for 225Ac. This study aimed to design and synthesize two novel 225Ac-labeled RGD peptides, [225Ac]Ac-Macropa-c(RGDyK) ([225Ac]1) and [225Ac]Ac-Macropa-[c(RGDyK)]2 ([225Ac]2), and to evaluate their potential for targeted alpha therapy (TAT) of glioblastoma. Further, whether combination therapy with homoarginine (hArg), a modulator of lysosomal function, could further improve therapeutic efficacy was investigated. In Colon-26 cells, [225Ac]2 demonstrated significantly higher cellular uptake and cytotoxicity than [225Ac]1. In Colon-26 tumor-bearing mice, [225Ac]2 exhibited higher tumor accumulation and significant tumor growth inhibition. In GL261 glioblastoma cells, [225Ac]2 showed comparable cellular uptake to that in Colon-26 cells, and combination with hArg in vitro improved its cytotoxicity. However, no significant difference in therapeutic efficacy was observed between the hArg-treated and control groups in the orthotopic GL261 glioblastoma mouse model. The results of this study indicate the potential of 225Ac-labeled RGD peptides incorporating Macropa as a chelator as promising agents for TAT. However, the further optimization of combination strategies and pharmacokinetics is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa920-1192, Japan.
- Graduate School of Engineering, Kyoto University Katsura, Kyoto University, Nishikyo-ku, Kyoto615-8510, Japan.
- Research Center for Accelerator and Radioisotope Science (RARiS), Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi982-0826, Japan.
- Institute for Radiation Sciences (IRS), The University of Osaka, 1-1 Machikaneyama-cho, Toyonaka, Osaka560-0043, Japan.
- Department of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba263-8555, Japan.
- Department of Bioactive Molecules, Pharmacology, Gifu Pharmaceutical University, Gifu501-1196, Japan.
ORCID-Profile: Takeshi Fuchigami, Kenji Mishiro, Kazuma Ogawa
Förderung
- Japan Society for the Promotion of Science
- Terumo Foundation for Life Sciences and Arts
Zitieren
APA
Echigo, H., Munekane, M., Fuchigami, T., Mishiro, K., Kikunaga, H., Tsukada, K., Yokokita, T., Shirasaki, K., Ichinose, J., Hinoi, E., Kinuya, S., & Ogawa, K. (2026). Macropa-Based 225Ac-Labeled RGD Peptides for Targeted Alpha Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00344
Vancouver
Echigo H, Munekane M, Fuchigami T, Mishiro K, Kikunaga H, Tsukada K, et al. Macropa-Based 225Ac-Labeled RGD Peptides for Targeted Alpha Therapy. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00344
BibTeX
@article{Echigo2026,
author = {Echigo, Hiroaki and Munekane, Masayuki and Fuchigami, Takeshi and Mishiro, Kenji and Kikunaga, Hidetoshi and Tsukada, Kazuaki and Yokokita, Takuya and Shirasaki, Kenji and Ichinose, Jun and Hinoi, Eiichi and Kinuya, Seigo and Ogawa, Kazuma},
title = {Macropa-Based 225Ac-Labeled RGD Peptides for Targeted Alpha Therapy},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c00344}
}
EUVIMED